Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

annickawaechter 2649 posts  |  Last Activity: Aug 18, 2016 5:22 PM Member since: Mar 28, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • annickawaechter annickawaechter Aug 18, 2016 5:22 PM Flag

    Indeed. $0,63 now, we are getting there

    Sentiment: Strong Sell

  • Reply to

    ATM

    by kerx4sale Jul 27, 2016 4:22 AM
    annickawaechter annickawaechter Aug 5, 2016 1:23 AM Flag

    I was thinking exactly the same thing!

    Sentiment: Strong Sell

  • annickawaechter annickawaechter Aug 1, 2016 4:42 PM Flag

    Real results even $100,000 worse! They are never going to be profitable.

    Sentiment: Strong Sell

  • Then buy gran colombia gold corp or gcm.to

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Jul 25, 2016 1:15 AM Flag

    “When we tried to grind up titanium-gold, we couldn’t,” she recalled. “I even bought a diamond (coated) mortar and pestle, and we still couldn’t grind it up.”

    The team measured the hardness of the beta form of the crystal in conjunction with colleagues at Texas A&M University’s Turbomachinery Laboratory and at the National High Magnetic Field Laboratory at Florida State University, Morosan and Svanidze also performed other comparisons with titanium. For biomedical implants, for example, two key measures are biocompatibility and wear resistance. Because titanium and gold by themselves are among the most biocompatible metals and are often used in medical implants, the team believed titanium-3-gold would be comparable. In fact, tests by colleagues at the University of Texas MD Anderson Cancer Center in Houston determined that the new alloy was even more biocompatible than pure titanium. The story proved much the same for wear resistance: Titanium-3-gold also outperformed pure titanium.
    This is very bad news for Amedica.

    Sentiment: Strong Sell

  • Rice lab discovers titanium-gold alloy that is four times harder than most steels
    Titanium is the leading material for artificial knee and hip joints because it’s strong, wear-resistant and nontoxic, but an unexpected discovery by Rice University physicists shows that the gold standard for artificial joints can be improved with the addition of some actual gold.
    “It is about 3-4 times harder than most steels,” said Emilia Morosan, the lead scientist on a new study in Science Advances that describes the properties of a 3-to-1 mixture of titanium and gold with a specific atomic structure that imparts hardness. “It’s four times harder than pure titanium, which is what’s currently being used in most dental implants and replacement joints.”
    Morosan, a physicist who specializes in the design and synthesis of compounds with exotic electronic and magnetic properties, said the new study is “a first for me in a number of ways. This compound is not difficult to make, and it’s not a new material.”
    In fact, the atomic structure of the material — its atoms are tightly packed in a “cubic” crystalline structure that’s often associated with hardness — was previously known. It’s not even clear that Morosan and former graduate student Eteri Svanidze, the study’s lead co-author, were the first to make a pure sample of the ultrahard “beta” form of the compound. But due to a couple of lucky breaks, they and their co-authors are the first to document the material’s remarkable properties
    “This began from my core research,” said Morosan, professor of physics and astronomy, of chemistry and of materials science and nanoengineering at Rice. “We published a study not long ago on titanium-gold, a 1-to-1 ratio compound that was a magnetic material made from nonmagnetic elements. One of the things that we do when we make a new compound is try to grind it into powder for X-ray purposes. This helps with identifying the composition, the purity, the crystal structure and other structural properties.

    Sentiment: Strong Sell

  • annickawaechter annickawaechter Jul 23, 2016 5:56 AM Flag

    Median indeed

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Jul 22, 2016 12:42 PM Flag

    Back on top

    Sentiment: Strong Buy

  • Gold Miners Face Potential Crisis as World Governments Boost Royalties
    Dave Forest: Governments in resource-rich nations worldwide are still scrambling to adjust to lower commodities prices. With officials in a number of countries making significant moves this week to fix their finances — one way or another.

    The trend toward government sales of resource assets continued. With Russia publishing guidelines for a planned sale of a 19.5% stake in state-owned oil and gas firm Rosneft.

    But not all governments have assets to sell to raise cash. And some countries are looking to fill their coffers by raising royalties on mining projects.

    One of those is Indonesia. Which announced Sunday that it is going ahead with an across-the-board rise in royalty rates for all metals produced in the country.

    A spokesman for Indonesia’s Energy Ministry told reporters that royalties on gold will rise most significantly — jumping to 3.75%, from a former 1%. Silver will rise to 3.25%, from 1%, and nickel will jump to 2%, from a former 0.9%.

    The good news for miners is that royalties on copper — one of Indonesia’s key mining products — are only rising slightly. To 4%, from a former 3.75%.

    At the same time, officials in the Philippines are looking to use a similar strategy to boost revenue. With that country’s senate introducing a bill Monday to raise mining royalties to 10% of gross revenues.

    The measure would reportedly apply to all types of mines. With the bill also specifying that the government could take a 55% share of adjusted revenues — if such an amount was greater than the 10% off-the-top royalty.

    Sentiment: Strong Sell

  • Gold Miners Face Potential Crisis as World Governments Boost Royalties
    Dave Forest: Governments in resource-rich nations worldwide are still scrambling to adjust to lower commodities prices. With officials in a number of countries making significant moves this week to fix their finances — one way or another.

    The trend toward government sales of resource assets continued. With Russia publishing guidelines for a planned sale of a 19.5% stake in state-owned oil and gas firm Rosneft.

    But not all governments have assets to sell to raise cash. And some countries are looking to fill their coffers by raising royalties on mining projects.

    One of those is Indonesia. Which announced Sunday that it is going ahead with an across-the-board rise in royalty rates for all metals produced in the country.

    A spokesman for Indonesia’s Energy Ministry told reporters that royalties on gold will rise most significantly — jumping to 3.75%, from a former 1%. Silver will rise to 3.25%, from 1%, and nickel will jump to 2%, from a former 0.9%.

    The good news for miners is that royalties on copper — one of Indonesia’s key mining products — are only rising slightly. To 4%, from a former 3.75%.

    At the same time, officials in the Philippines are looking to use a similar strategy to boost revenue. With that country’s senate introducing a bill Monday to raise mining royalties to 10% of gross revenues.

    The measure would reportedly apply to all types of mines. With the bill also specifying that the government could take a 55% share of adjusted revenues — if such an amount was greater than the 10% off-the-top royalty.

    Sentiment: Strong Sell

  • annickawaechter by annickawaechter Jul 18, 2016 2:47 AM Flag

    Come on, which central bank, institution or very rich people want to buy gold at this price. Gold should belong where it should be and that is around $800.

    Sentiment: Strong Sell

  • annickawaechter by annickawaechter Jul 18, 2016 2:43 AM Flag

    Only an idiot buy trackers like NUGT right now. Come on, which institution, nation or very rich people want gold at $1300. Gold will be were it should be and that is at $800

    Sentiment: Strong Buy

  • Reply to

    Situation in Turkey back under controll.

    by alexander.johannes Jul 16, 2016 12:08 AM
    annickawaechter annickawaechter Jul 18, 2016 2:18 AM Flag

    As expected gold is continuing its' downtrend from last week. Back under 1300 and then 1200,1100. Gold will be under 1000 buy EOY.

    Sentiment: Strong Sell

  • annickawaechter annickawaechter Jul 15, 2016 2:50 PM Flag

    Lol... Disruptive technology... If it was so diruptive they would have had a lot more partners or would already have been bought out by Stryker or Zimmer Biomet.

    0,11 dollar/share book value!

    Sentiment: Strong Sell

  • Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
    (2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
    Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.

    Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
    Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually

    US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.

    Sentiment: Strong Buy

  • Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
    (2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
    Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.

    Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
    Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually

    US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.

    Sentiment: Strong Buy

  • annickawaechter annickawaechter Jul 12, 2016 2:11 AM Flag

    Too low of course. A fair value of $150/share based on the current 10 million shares outstanding and the two phase 3 products only, not calculating the rest of the pipeline.

    Sentiment: Strong Buy

  • Reply to

    AEZS is a strong buy

    by annickawaechter Jul 9, 2016 8:44 AM
    annickawaechter annickawaechter Jul 12, 2016 1:01 AM Flag

    rating reiterated by equities researchers at HC Wainwright in a research report issued on Sunday.

    Shares of Aeterna Zentaris (NASDAQ:AEZS) traded up 2.42% during midday trading on Friday, reaching $3.38. 107,781 shares of the company traded hands. Aeterna Zentaris has a 1-year low of $2.60 and a 1-year high of $25.00. The company’s market capitalization is $33.59 million. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.52.

    An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC boosted its stake in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned about 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent filing with the SEC.

    AEZS has been the subject of several other research reports. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, May 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $9.00 price target (down previously from $13.00) on shares of Aeterna Zentaris in a research report on Monday, April 4th.

    Sentiment: Strong Buy

  • Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
    (2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
    Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.

    Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
    Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually

    US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.

    Sentiment: Strong Buy

  • Strong cash position $33m as of March 31st, cash burn $2.8m/month. Two main products: (1) Zoptrex, phase 3 results available this quarter which could be the first FDA and EMA approved treatment for endometrial cancer
    (2) Macrilen, phase 3 results available this quarter, to diagnose AGHD and AGHD after TBI. A much less invasive, less time consuming and less risky (no risk for hypoglycemic coma) compared to the insuline tolerance test. Two partnerships signed for Zoptrex for two of the most difficult-though very large and commercially very attractive - regions in the world: China + SouthEast Asia.
    Two succesfully phase 2 results for Zoptrex for ovarian and prostate cancer, ready to go into phase 3.

    Potential revenues for Zoptrex for endometrial cancer in the US alone: $300million/annually
    Potential revenues for Macrilen (including AGHD caused by TBI) in the US alone: upto $200million/annually

    US sales force already available b/c the company is already selling products for endocrinology, oncology and womens' health on a commission basis.

    Sentiment: Strong Buy

SVFC
0.00010.0000(0.00%)Aug 24 10:13 AMEDT